Fig. 1: Overall survival of both patient groups. | Genes & Immunity

Fig. 1: Overall survival of both patient groups.

From: Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients

Fig. 1

Group-1 patients (7 patients) received individualized multimodal immunotherapy after local therapy (surgery and/or radio(chemo)therapy). Group-2 patients (25 patients, one loss of follow-up) received ICD therapy during TMZ cycles (at least one cycle) followed by active specific immunotherapy with dendritic cell vaccines (IO-Vac®) after all chemotherapy.

Back to article page